Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review
Yiting Dong, Jiachen Xu, Boyang Sun, et al.
Molecular Diagnosis & Therapy (2022) Vol. 26, Iss. 2, pp. 203-227
Open Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

Current treatments for non-small cell lung cancer
Qianqian Guo, Liwei Liu, Zelong Chen, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 70
Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma (Review)
Ruizhu Sun, Zhansheng Hou, Yankui Zhang, et al.
Oncology Letters (2022) Vol. 24, Iss. 5
Open Access | Times Cited: 41
MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: Clinical Challenges and Opportunities
Kang Qin, Lingzhi Hong, Jianjun Zhang, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 612-612
Open Access | Times Cited: 25
Novel therapeutic strategies for rare mutations in non-small cell lung cancer
Qitao Gou, Qiheng Gou, Xiaochuan Gan, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 13
Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy
Martina Ruglioni, Stefania Crucitta, Giovanna Irene Luculli, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 201, pp. 104424-104424
Open Access | Times Cited: 12
Reducing target binding affinity improves the therapeutic index of anti-MET antibody-drug conjugate in tumor bearing animals
Amita Datta‐Mannan, Hiuwan Choi, Zhaoyan Jin, et al.
PLoS ONE (2024) Vol. 19, Iss. 4, pp. e0293703-e0293703
Open Access | Times Cited: 9
SpaRx: elucidate single-cell spatial heterogeneity of drug responses for personalized treatment
Ziyang Tang, Xiang Liu, Zuotian Li, et al.
Briefings in Bioinformatics (2023) Vol. 24, Iss. 6
Open Access | Times Cited: 17
Imidazopyridine-based kinase inhibitors as potential anticancer agents: A review
Fariba Peytam, Zahra Emamgholipour, Ali Mousavi, et al.
Bioorganic Chemistry (2023) Vol. 140, pp. 106831-106831
Closed Access | Times Cited: 12
Suppression of galectin-4 attenuates peritoneal metastasis of poorly differentiated gastric cancer cells
Hiroko Ideo, Akiko Tsuchida, Yoshio Takada, et al.
Gastric Cancer (2023) Vol. 26, Iss. 3, pp. 352-363
Open Access | Times Cited: 11
Role and Function of Receptor Tyrosine Kinases in BRAF Mutant Cancers
Bernhard Biersack, Lubna H. Tahtamouni, Michael Höpfner
Receptors (2024) Vol. 3, Iss. 1, pp. 58-106
Open Access | Times Cited: 4
Targeting ABCD1-ACOX1-MET/IGF1R axis suppresses multiple myeloma
Zhannan Han, Zhibo Yan, Zhehan Ma, et al.
Leukemia (2025)
Closed Access
Prognostic value of c-MET in oesophageal squamous cell carcinoma: a study based on the mRNA expression in TCGA database and a meta-analysis
Qiqi Zhang, Xiujuan Li, Jian Li, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access
Adverse event signal analysis of type Ib MET tyrosine kinase inhibitors based on food and drug administration adverse event reporting system
J.G. Wang, Rong Ma, Binbin Qu, et al.
Expert Opinion on Drug Safety (2025), pp. 1-10
Open Access
Targeting c-MET Alterations in Cancer: A Review of Genetic Drivers and Therapeutic Implications
Michelle Ji, Shridar Ganesan, Bing Xia, et al.
Cancers (2025) Vol. 17, Iss. 9, pp. 1493-1493
Open Access
Biologics for novel driver altered non-small cell lung cancer: potential and pitfalls
Gianluca Russo, Claudia Scimone, Lucia Palumbo, et al.
Critical Reviews in Oncology/Hematology (2025), pp. 104748-104748
Open Access
A Review of the Molecular Determinants of Therapeutic Response in Non-Small Cell Lung Cancer Brain Metastases
Catherine Boldig, Kimberly Boldig, Sepideh Mokhtari, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 6961-6961
Open Access | Times Cited: 3
AI predictive modeling of survival outcomes for renal cancer patients undergoing targeted therapy
Yaoqi Yu, Ji-rui Niu, Yin Yu, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Closed Access | Times Cited: 3
MET alterations in advanced pulmonary sarcomatoid carcinoma
Gong Chen, Huihua Xiong, A. K. Qin, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 15
Remarkable response to capmatinib in a patient with intrahepatic cholangiocarcinoma harboring TFG-MET fusion
A. Ueta, Atsushi Yamada, Masahiro Yoshioka, et al.
International Cancer Conference Journal (2024) Vol. 13, Iss. 3, pp. 199-203
Closed Access | Times Cited: 2
Toxicity burden patterns of MET-selective tyrosine kinase inhibitors: evidence from real-world pharmacovigilance
Wenjie Li, Wei Wang
Investigational New Drugs (2024) Vol. 42, Iss. 3, pp. 335-339
Closed Access | Times Cited: 2
Advances in MET tyrosine kinase inhibitors in gastric cancer
Yifan Zhang, Lin Shen, Zhi Peng
Cancer Biology and Medicine (2024), pp. 1-15
Open Access | Times Cited: 2
The MET Oncogene: An Update on Targeting Strategies
Simona Gallo, Consolata Beatrice Folco, Tiziana Crepaldi
Pharmaceuticals (2024) Vol. 17, Iss. 11, pp. 1473-1473
Open Access | Times Cited: 2
HGF/c-MET: A Potential Target for the Treatment of Various Cancers
Kuttiappan Anitha, Kamal Dua, Dinesh Kumar Chellappan, et al.
Current Enzyme Inhibition (2023) Vol. 19, Iss. 2, pp. 71-80
Closed Access | Times Cited: 4
Molecular Targeting in Non-Small Cell Lung Cancer: Advances in EGFR, ROS1, ALK, and MET Pathways
Daniel Rosas, Can Jones, Brian Hunis, et al.
Journal of Oncology Research and Therapy (2024) Vol. 9, Iss. 2
Open Access | Times Cited: 1
Research into overcoming drug resistance in lung cancer treatment using CRISPR-Cas9 technology: a narrative review
Bin Liu, Ziyu Wang, Meng Gu, et al.
Translational Lung Cancer Research (2024) Vol. 13, Iss. 8, pp. 2067-2081
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top